Pharmacological analysis of extracellular dopamine and metabolites in the striatum of conscious as/agu rats, mutants with locomotor disorder
The as/agu rat is a spontaneously occurring mutation which exhibits locomotor abnormalities, reduced tyrosine hydroxylase levels in the substantia nigra and lower extracellular levels of dopamine. The animal could represent a model of some human locomotor disorders. High-potassium medium evoked a 460% rise of dopamine levels in control rats but double this in mutants. Amphetamine increased extracellular dopamine by 710% in controls and 1480% in mutants. Clorgyline produced a small increase of dopamine levels in controls but an 1170% increase in mutants. The uptake inhibitor nomifensine increased dopamine levels by 910% in controls but only 270% in mutants. After treatment with benserazide plus L-DOPA, an acute injection of L-DOPA evoked a release of dopamine which was twice as large in the as/agu rats compared with controls. The results show reduced extracellular dopamine in as/agu rats when the locomotor disorder is apparent, but there has been little loss of tyrosine hydroxylase. The responses to drugs are qualitatively different from those obtained using 6-hydroxydopamine.Overall, the effects of compounds affecting aminergic neurons suggest that one possible mechanism for the neuronal abnormality in as/agu rats is a defective regulation of dopamine release from striatal terminals.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2000 |
|---|---|
| Erschienen: |
2000 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:100 |
|---|---|
| Enthalten in: |
Neuroscience - 100(2000), 1 vom: 29., Seite 45-52 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Campbell, J M [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 06.11.2000 Date Revised 12.07.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM109165772 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM109165772 | ||
| 003 | DE-627 | ||
| 005 | 20231222150745.0 | ||
| 007 | tu | ||
| 008 | 231222s2000 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0364.xml |
| 035 | |a (DE-627)NLM109165772 | ||
| 035 | |a (NLM)10996457 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Campbell, J M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacological analysis of extracellular dopamine and metabolites in the striatum of conscious as/agu rats, mutants with locomotor disorder |
| 264 | 1 | |c 2000 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 06.11.2000 | ||
| 500 | |a Date Revised 12.07.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The as/agu rat is a spontaneously occurring mutation which exhibits locomotor abnormalities, reduced tyrosine hydroxylase levels in the substantia nigra and lower extracellular levels of dopamine. The animal could represent a model of some human locomotor disorders. High-potassium medium evoked a 460% rise of dopamine levels in control rats but double this in mutants. Amphetamine increased extracellular dopamine by 710% in controls and 1480% in mutants. Clorgyline produced a small increase of dopamine levels in controls but an 1170% increase in mutants. The uptake inhibitor nomifensine increased dopamine levels by 910% in controls but only 270% in mutants. After treatment with benserazide plus L-DOPA, an acute injection of L-DOPA evoked a release of dopamine which was twice as large in the as/agu rats compared with controls. The results show reduced extracellular dopamine in as/agu rats when the locomotor disorder is apparent, but there has been little loss of tyrosine hydroxylase. The responses to drugs are qualitatively different from those obtained using 6-hydroxydopamine.Overall, the effects of compounds affecting aminergic neurons suggest that one possible mechanism for the neuronal abnormality in as/agu rats is a defective regulation of dopamine release from striatal terminals | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Dopamine Agents |2 NLM | |
| 650 | 7 | |a Dopamine Uptake Inhibitors |2 NLM | |
| 650 | 7 | |a Monoamine Oxidase Inhibitors |2 NLM | |
| 650 | 7 | |a Nomifensine |2 NLM | |
| 650 | 7 | |a 1LGS5JRP31 |2 NLM | |
| 650 | 7 | |a Levodopa |2 NLM | |
| 650 | 7 | |a 46627O600J |2 NLM | |
| 650 | 7 | |a Amphetamine |2 NLM | |
| 650 | 7 | |a CK833KGX7E |2 NLM | |
| 650 | 7 | |a Clorgyline |2 NLM | |
| 650 | 7 | |a LYJ16FZU9Q |2 NLM | |
| 650 | 7 | |a Potassium |2 NLM | |
| 650 | 7 | |a RWP5GA015D |2 NLM | |
| 650 | 7 | |a Dopamine |2 NLM | |
| 650 | 7 | |a VTD58H1Z2X |2 NLM | |
| 700 | 1 | |a Gilmore, D P |e verfasserin |4 aut | |
| 700 | 1 | |a Russell, D |e verfasserin |4 aut | |
| 700 | 1 | |a Growney, C A |e verfasserin |4 aut | |
| 700 | 1 | |a Favor, G |e verfasserin |4 aut | |
| 700 | 1 | |a Kennedy, A K |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, R W |e verfasserin |4 aut | |
| 700 | 1 | |a Payne, A P |e verfasserin |4 aut | |
| 700 | 1 | |a Stone, T W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuroscience |d 1976 |g 100(2000), 1 vom: 29., Seite 45-52 |w (DE-627)NLM000132403 |x 1873-7544 |7 nnns |
| 773 | 1 | 8 | |g volume:100 |g year:2000 |g number:1 |g day:29 |g pages:45-52 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 100 |j 2000 |e 1 |b 29 |h 45-52 | ||